Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

Journal of Clinical Oncology

Volumn 29, Issue 35, 2011, Pages 4682-4687

  D'Amico, Anthony V ^a,b   Chen, Ming Hui ^c   Crook, Juanita ^d   Armstrong, John G ^f   Malone, Shawn ^e   Steigler, Allison ^g   Dunne, Mary ^e   Kantoff, Philip W ^a,b   Denham, James W ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e OTTAWA REGIONAL CANCER CENTRE   (Canada)

^f ST LUKE S HOSPITAL   (Ireland)

^g UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN SUPPRESSION THERAPY; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; UNITED STATES;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 83255188846     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.0726     Document Type: Article

References (24)

1. Gleason DF, Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
2. Bolla M, de Reijke TM, Van Tienhoven G, et al.: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527, 2009
3. Hanks GE, Pajak TF, Porter A, et al.: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21:3972-3978, 2003 (Pubitemid 46606211)
4. Mohler J, Bahnson RR, Boston B, et al.: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8:162-200, 2010
5. D'Amico AV, Chen MH, Renshaw AA, et al.: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295, 2008 (Pubitemid 351159365)
6. Denham JW, Steigler A, Lamb DS, et al.: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005 (Pubitemid 41614795)
7. Beahrs O, Henson DE, Hutter RVP, et al. (eds): American Joint Committee on Cancer: Manual for Staging of Cancer (ed 4). Philadelphia, PA, JB Lippincott, 1992
8. Roach M 3rd, Bae K, Speight J, et al.: Shortterm neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008 (Pubitemid 351264352)
9. Jones CU, Hunt D, McGowan DG, et al.: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365:107-118, 2011
10. Armstrong JG, Gillham CM, Dunne MT, et al.: A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 81:35-45, 2011
11. D'Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998 (Pubitemid 28445094)
12. Agresti A (ed): An Introduction to Categorical Data Analysis (ed 2). New York, NY, John Wiley & Sons, 2002, pp 16-52
13. Hollander M, Wolfe DA (eds): Nonparametric Statistical Methods (ed 2). New York, NY, John Wiley & Sons, 1999, pp 189-269
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:447-457, 1958
15. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
16. Gaynor JJ, Feuer EJ, Tan CC, et al.: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
17. Neter J, Wassermann W, Kutner M (eds): Simultaneous inferences and other topics in regression analyses-1, in Applied Linear Regression Models. Homewood, IL, Irwin, 1983, pp 150-153
18. Shao YH, Demissie K, Shih W, et al.: Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 101:1280-1283, 2009
19. Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotropin-releasing hormone antagonists in prostate cancer. BJU Int 11:1580-1584, 2009
20. D'Amico AV, Chen MH, Renshaw AA, et al.: Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 26:2979-2983, 2008
21. Scher HI, Logothetis C, Molina A, et al. Improved survival outcomes in clinically relevant patient subgroups from COU-AA 301, a phase III study of abiraterione acetate (AA) plus prednisone (P) in patients with metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxelbased chemotherapy. J Clin Oncol 29:6s, 2011 (suppl 7; abstr LBA4)
22. Dearnaley DP, Sydes MR, Graham JD, et al.: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475-487, 2007 (Pubitemid 46805903)
23. D'Amico AV, Renshaw AA, Loffredo B, et al.: Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110:1723-1728, 2007 (Pubitemid 47557296)
24. Albertsen PC, Hanley JA, Barrows GH, et al.: Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248-1253, 2005 (Pubitemid 41535365)